ATOX1 and breast carcinoma: We found that breast cancer patients at stage III of disease with high cytoplasmatic ATOX1 levels in their primary tumor have a 65% higher EFS chance after copper depletion treatment with TM (median EFS is 40.4 months for low ATOX1 patients, while not yet reached for high ATOX1 patients).